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ABSTRACT
Aberrant DNA methylation is often associated with
cancer and the formation of tumors; however, the
underlying mechanisms, in particular the recruit-
ment and regulation of DNA methyltransferases
remain largely unknown. In this study, we identified
USP7 as an interaction partner of Dnmt1 and UHRF1
in vivo. Dnmt1 and USP7 formed a soluble dimer
complex that associated with UHRF1 as a trimeric
complex on chromatin. Complex interactions were
mediated by the C-terminal domain of USP7 with the
TS-domain of Dnmt1, whereas the TRAF-domain of
USP7 bound to the SRA-domain of UHRF1. USP7
was capable of targeting UHRF1 for deubiquitination
and affects UHRF1 protein stability in vivo.
Furthermore, Dnmt1, UHRF1 and USP7 co-localized
on silenced, methylated genes in vivo. Strikingly,
when analyzing the impact of UHRF1 and USP7 on
Dnmt1-dependent DNA methylation, we found that
USP7 stimulated both the maintenance and de novo
DNA methylation activity of Dnmt1 in vitro.
Therefore, we propose a dual role of USP7, regulat-
ing the protein turnover of UHRF1 and stimulating
the enzymatic activity of Dnmt1 in vitro and in vivo.
INTRODUCTION
In mammals, the majority of C-5-cytosine methylation oc-
curs at CpG dinucleotides that are modiﬁed to 70–80% in
a cell type-speciﬁc pattern and generally associated with
repressed states of chromatin (1–4). DNA methylation
contributes to epigenetic processes such as differentiation
and development, transcriptional regulation, preservation
of chromosomal stability, silencing of repetitive elements,
genomic imprinting, X-chromosome inactivation and
DNA repair (2,3). Dnmt3a and Dnmt3b are mainly
involved in de novo establishment of DNA methylation
marks, whereas the maintenance DNA methyltransferase
Dnmt1 maintains methylation patterns on the newly syn-
thesized daughter strand during replication (5,6). Mice
depleted for the DNA methyltransferases revealed devel-
opmental defects and die early during embryogenesis (7,8).
Aberrant DNA methylation patterns are often associated
with cancer (9), genome-wide hypo- and hypermethylation
correlates with genomic instability, reactivation of retro-
transposons, repression of tumor suppressor genes and
loss of genomic imprinting (LOI). The DNA methyltrans-
ferases were found to interact with many chromatin-
associated factors such as methyl-binding proteins
(MBD2, MeCP2), histone deacetylases (HDAC), histone
methyl transferases (HMT), transcriptional repressors,
chromatin remodeling enzymes and Polycomb group pro-
teins (10,11). However, so far the only Dnmt1 complex
puriﬁed by means of chromatographic fractionation from
HeLa nuclear extracts was a transcription repression com-
plex consisting of Dnmt1, pRB, E2F1 and HDAC1 (12).
Recently, UHRF1 (also known as ICBP90 in human or
NP95 in mouse) has been shown to be essential in main-
taining genomic DNA methylation (13,14). The DNA of
UHRF1-deﬁcient ES cells exhibited low DNA methyla-
tion levels and methylation defects of the imprinted
genes (14), an effect reminiscent of Dnmt1 knockout in
ES cells and mice (7). UHRF1 strongly associates with
heterochromatin (15,16) and binds preferentially to
hemi-methylated DNA via its SRA domain (13,17–19).
The latter was also shown to interact with the TS
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that UHRF1 would recruit Dnmt1 to heterochromatin to
maintain DNA methylation during replication.
Furthermore, UHRF1 belongs to the class of Ring
ﬁnger-type E3-ubiquitin ligases (22) possessing in vitro
autoubiquitinylation activity (15,16,23). UHRF1 does
also target histones for ubiquitinylation in vitro and
in vivo, with a preference for histone H3 (15,16).
USP7 (also known as HAUSP) was initially identiﬁed in
promyelocytic leukemia nuclear bodies (PML) of herpes
simplex virus infected cells (24). It regulates the stability of
p53 and MDM2 through its deubiquitination activity
(25–28). Furthermore, USP7 has been shown to associate
with other factors and substrates including EBNA1 (29),
DAXX (30), FOXO4 (31), PTEN (32) and is crucial for
development, as mice depleted for USP7 die during em-
bryogenesis (33). USP7 was shown to silence the homeotic
genes through Polycomb in Drosophila (34). In particular,
the GMP-synthetase interacted with USP7 to enhance the
removal of the active ubiquitin mark from histone H2B
and to act as a transcriptional corepressor (35).
We biochemically puriﬁed human Dnmt1 and show that
it is associated primarily with USP7 and co-assembles with
UHRF1 on DNA, forming a trimeric complex that asso-
ciates with silenced genes in vivo. We show a dual role for
USP7 in the complex, ﬁrst stimulating the enzymatic
activity of Dnmt1 and second regulating the stability of
the UHRF1 protein.
MATERIALS AND METHODS
Cell culture
All cell lines were grown at 37 C, 5% CO2 in medium
containing 10% FBS (GIBCO), 100 U/ml penicillin and
100mg/ml streptomycin (GIBCO). Human cervix carcin-
oma cells (HeLa S3 cells; ATCC 161) were grown in spin-
ner ﬂasks in RPMI 1640 medium (GIBCO) with a cell
density of  1 10
6cells/ml. Human colon adenocarcin-
oma cells HCT-116 (ATCC 581) were cultivated as
mono-layers in D-MEM medium (GIBCO) and grown
to a conﬂuency of 60–70%. LS174TR1 cells, expressing the
Tet-repressor (36,37) were grown in RPMI 1640/HEPES
medium (GIBCO) supplemented with 10mg/ml blasticidin.
LS174TR1 cells with plasmids carrying either shRNA
(LS88) or N-myc-USP7 (LS89) under the control of a
tetracycline/doxycycline inducible promoter were cultiv-
ated as LS174TR1 but supplemented with 400mg/ml
Zeocin (28,38). LS174TR1 cells and their derivates were
kindly provided by M. Maurice. For doxycycline treatment,
cells were seeded on a 10cm tissue culture plate with a cell
number giving rise to 50–60% conﬂuency on the day
of harvest. Cells were grown in RPMI1640/HEPES
(GIBCO) supplemented with blasticidin (10mg/ml),
Zeocin (200mg/ml), TET-FBS (Clontech 631106) and
1.0mg/ml doxycycline. The parental LS174TR1 cells were
used as a negative control in all experiments. H1299
(p53
 / ; ATCC: CRL-5803) non-small lung cancer cells
were cultivated as mono-layers in D-MEM medium
(GIBCO). Protein half-life studies were performed by in-
cubating cells with cycloheximide (Sigma, 100mg/ml) and
proteasome inhibitor MG132 (Sigma, 20mM) for the indi-
cated time points. Transfection reactions with the Fugene6
reagent (Roche) were performed in six-well plates with
3 10
5cells/well with 2.0mg total plasmid DNA for 48h.
For protein half-life studies, cells were split 1:4 36h
post-transfection and treated with cycloheximide for the
indicated time points.
For knockdown experiments, 2 10
6 HCT-116 cells
were electroporated with 80pmol validated siRNAs
(siGENOME non-targeting siRNA #1, Thermo
Scientiﬁc Dharmacon; UHRF1 Silencer Select siRNA
and USP7 Silencer Validated siRNA, both Applied
Biosystems) for 10ms with 350V and subsequently
seeded in six-well plates for 48h.
Plasmids and constructs
The plasmid pFastBAcHTa-Dnmt1 with an N-terminal
6 His-tag and TEV cleavage site were a kind gift of
F. Lyko. The cDNA of the full-length Dnmt3b2 (kind
gift of F. Lyko) was PCR-ampliﬁed and cloned into a
modiﬁed pet11 bacterial expression vector (Novagen)
carrying an N-terminal Flag-tag and a C-terminal
Thrombin cleavage site followed by a 6 His-tag (pETM-
Dnmt3b2). Full-length human Dnmt3a was PCR-ampliﬁed
from a cDNA clone (RZPD, IRATp970A0473D) and
cloned in-frame into the pENTR3C-vector (Invitrogen)
with BamHI/EcoRI. Full-length USP7/HAUSP and the
TRAF domain of USP7 (amino acid 1–215, without stop
codon) were PCR ampliﬁed on pCin4-HAUSP [kindly
provided by Yigong Shi, (39)] and cloned into the
pENTR SD D TOPO vector (Invitrogen). USP7 C223S
mutant was generated by SOE-PCR and transferred into
the pDONR221 vector (Invitrogen). The GST fusion con-
structs of USP7-domains 2 (amino acid 212–561),
3 (amino acid 561–916) and 4 (amino acid 913–1102),
cloned as BamHI/XhoI fragments in pGEX-2T (GE
Healthcare), were kindly provided by Prof. Dobner.
UHRF1 and UHRF1RING (without stop codon) and
the SRA domain (TEV protease cleavage site, amino acid
409–635) of UHRF1 were PCR-ampliﬁed on pcDNA3.1-
ICBP90/UHRF1 [kindly provided by Yusuke Nakamura,
(17)] and cloned into the pENTR SD D TOPO vector
(Invitrogen). The correct sequence of all plasmids was
veriﬁed by sequencing (sequences of plasmids and
oligonucleotides on request). pENTR3C-Dnmt3a,
pENTR-USP7 and pDONR221-USP7 C223S were subse-
quently transferred via LR-reaction (Invitrogen) into
pDEST10 (Invitrogen) and pENTR-SRA into pDEST20
(Invitrogen) creating expression clones for baculovirus
generation. pENTR-UHRF1, pENTR-UHRF1RING
and pENTR-TRAF-domain were transferred via LR-
reaction (Invitrogen) into pDM7 (pET11 based destination
vector with C-terminal 6 His-tag) and pGEX-4T1-DEST
(pGEX 4T1 based destination vector), respectively. For
transfection studies pIRES EGFP UHRF1-C-Flag and
pIRES EGFP N-HA-USP7 were used.
Antibodies
The following antibodies were used for western blot
analysis and immunoprecipitation: anti-actin (rabbit
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Dnmt3a D3A2-6A4, anti-Dnmt3b D3B2-2C1 (rat mono-
clonal antibodies, E. Kremmer, Helmholtz Gesellschaft),
anti-Flag (mouse monoclonal, Sigma M2 F1804), anti-
Penta-His (mouse monoclonal, Qiagen P-21315),
anti-ICBP90/UHRF1 [mousemonoclonal,generouslypro-
vided by C. Bronner, (40)], anti-Lamin A/C (rabbit poly-
clonal, Santa Cruz, sc-20681), anti-RNAPII CTD 8WG16
(mouse monoclonal, generously provided by D. Eick) and
anti-USP7 (rabbit polyclonal, Bethyl laboratories,
A300-033A). Irrelevant IgG control and horseradish
peroxidase-coupled secondary antibody antibodies were
purchased from Santa Cruz.
DNA methyltransferase assay
Typical DNA methyltransferase reaction (50ml) contained
20nM Dnmt1, non-methylated (LP35/37) or hemi-
methylated (LP35/36) oligonucleotides at 120–4320nM
(9 CpG), BSA at 0.2mg/mla n d
3H-SAM (GE Healthcare,
TRK581-250UCi, 9.25 MBeq with 1.0mCi/ml
63.0Ci/mmol) at 480nM in DNA methyltransferase
buffer (20mM Tris, pH 7.6, 1.0mM EDTA, 1.0mM
DTT). The reaction was started with the addition of
DNA, incubated at 37 C for 10–30min, and stopped
with 10ml of 10mM SAM (Sigma). The reaction was
spotted on DE81 ﬁlter (Whatman), washed three times
with 0.2M NH3HCO3, once with water and ethanol fol-
lowing drying and scintillation counting.
LP35: 50-GGTACGGATGCGGAATCGTCTAACGC
GTGGAATCGTCCCCTTGCGAATTTCGGTGTCGA
T-30, LP36: 50-CGTAXGGATGXGGAATXGTCTAA
XGXGTGGAATXGTCCCCTTGXGAATTTXGGTGT
XGAT-30, LP37: 50-ATCGACACCGAAATTCGCAAG
GGGACGATTCCACGCGTTAGACGATTCCGCATC
CGTACC-30 (X=C5-methyl group).
In vitro ubiquitinylation assay
Standard ubiquitinylation reactions (10ml) contained
100ng E1 activating enzyme (Biomol, UW9410), 300ng
E2 conjugating enzyme UBCH5c (BioMol, UW9070),
1.0mg ubiquitin (Sigma U-6253) or 100ng Flag-tagged
ubiquitin (Boston Biochem, U-120) and 250ng UHRF1
or UHRF1RING in 1 reaction buffer (50mM Tris
pH 7.5, 50mM NaCl, 5.0mM MgCl2, 0.05% NP40,
1.0mM DTT, 5.0mM ATP). The reaction was carried
out for 2h at 37 C and stopped with the addition of
HU-buffer and boiled for 10min at 65 C. Samples were
resolved by SDS–PAGE and ubiquitination reaction was
analyzed by western blot using antibodies directed against
the His-tag or Flag-tag. For autoubiquitinylation reac-
tions of UHRF1 in the presence of USP7 or USP7
C223S, contained 5.0 and 50ng of USP7/USP7 C223S
and were supplemented with 10mM DTT.
Immunoprecipitation
All steps were carried out on ice or at 4 C and buffers
supplemented with protease inhibitors PMSF (1.0mM),
Leupeptin (1–10mg/ml), Aprotinin, Pepstatin (1.0mg/ml)
prior to use. If not stated differently, the following IP
buffer was used for IP experiments: 50mM Tris pH 7.5,
150mM NaCl, 1.0mM EDTA, 0.05% NP-40.
Protein mixtures (recombinant proteins, nuclear ex-
tracts) were incubated with 50ml of proteinG sepharose
slurry in the presence of 1 IP-buffer, to analyze for un-
speciﬁc interaction [referred to as ‘preclearing beads’
(PG)].
The precleared sample/lysate was added to 50mlo f
proteinG sepharose charged with antibodies and
incubated for 2h at 4 C. The ‘beads’ were washed three
times with 1000ml IP buffer and resuspended in 50ml
La ¨ mmli dye, heated to 95 C and subjected to SDS–
PAGE following WB blot analysis.
Protein bands for identiﬁcation were sent for MALDI
analysis.
Preparation of whole-cell extracts
Cells from P15 tissue culture plates were resuspended in
150ml lysis buffer (20mM Tris pH 7.5, 100mM NaCl,
0.1mM EDTA, 0.5% NP40) following incubation on ice
for 30min, while vigorously vortexing every 10min. After
centrifugation (30min, 13000g,4  C) the supernatant
(WCE) was recovered.
Real-time reverse transcription–PCR
Total RNA was extracted from tumor cells in Trizol
(Invitrogen), depleted from DNA and subsequently puri-
ﬁed using DNase I and RNeasy Mini Kit, respectively
(Qiagen). Reverse transcription (RT) of total RNA was
performed using random hexamers (Roche Diagnostics)
and SuperScriptII reverse transcriptase (Invitrogen).
qPCR ampliﬁcations were performed in doublets as desc-
ribed for the ChIP analysis. Ampliﬁcation of the house-
keeping gene TATA-Box-binding-Protein (TBP) was per-
formed to standardize the amount of sample RNA.
Relative quantitation of gene expression was performed
using the ct method as described earlier (41). We
used the following primer pairs (50 !30-orientation):
SFRP1-F, CCTGGGACTCAGCACATTGA; SFRP1-R,
GATGGCCTCAGATTTCAACTCG; IGFBP3-F, GTC
CAAGCGGGAGACAGAATAT; IGFBP3-R, CCTGG
GACTCAGCACATTGA; HHIP-F, TGTACATCATTC
TTGGTGATGGG, HHIP-R, AGCCGTAGCACTGAG
CCTGT; HOXA7-F, TCAGGACCTGACAGGAAG
CG; HOXA7-R, TCAGGTAGCGGTTGAAGTGGA
and TBP-F, GCCCGAAACGCCGAATAT; TBP-R, CC
GTGGTTCGTGGCTCTCT.
Methylation-speciﬁc PCR
Genomic DNA of tumor cells was extracted with phenol
and chloroform, ethanol precipitated and dissolved in TE
buffer following standard procedures (42,43). We used the
EpiTect

Bisulﬁte Kit (Qiagen) for bisulﬁte-treatment of
DNA as recommended by the manufacturer. Methylation
status of the promoter region of the SFRP1, IGFBP3,
HHIP and HOXA7 genes was analyzed by Methylation-
speciﬁc PCR (MSP) using the following primer sets
(50 !30-orientation): methylated (SFRP1-M-F, TTTGT
AGTTTTCGGAGTTAGTGTCGC; SFRP1-M-R, CGA
CCCTCGACCTACGATCG; IGFBP3-M-F, GCGAGT
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CGCTATATAAAAACCG; HHIP-M-F, AGTAGTCGG
GTAGTTTCGGAATTTTC; HHIP-M-R, GAACCTTC
GAAACCAACCTCG; HOXA7-M-F, GAGTTTAGAT
AGACGGCGGC; HOXA7-M-R, CCGAAAACGCCTT
TATAACG) and unmethylated (SFRP1-U-F, TTTTGTA
GTTTTTGGAGTTAGTGTTGTGTG; SFRP1-U-R, C
AATAACAACCCTCAACCTACAATCAA; IGFBP3-
U-F, TTGGGTGAGTTTTGAGTTGTATGTTTTT;
IGFBP3-U-R, AAACACACCAACCACTATATAAAA
ACCAAA; HHIP-U-F, TTGTAGTAGTTGGGTAGTT
TTGGAATTTTT; HHIP-U-R, AAACCTTCAAAACC
AACCTCAAAA; HOXA7-U-F, GTTTGAGTTTAGAT
AGATGGTGGTG; HOXA7-U-R, CATCCAAAAACA
CCTTTATAACAAA).
MSP primer design was accomplished using Methyl
Primer Express (Applied Biosystems) using the following
criteria: CpG percentage >55%; observed/expected
CpG>65%; CpG length>300bp. The MSP reaction
contained 40ng DNA, 500nM of forward and reverse
primer, 2mM dNTPs, 1.5mM MgCl2, 1U Hot Start
Taq DNA polymerase and 1 Hot Start PCR Buffer
(MBI Fermentas). Conditions for MSP were 95 C for
4min, followed by 38 cycles of 94 C for 30s, 61 C for
30s and 72 C for 45s, with a ﬁnal extension cycle of
72 C for 10min. The PCR products were resolved by elec-
trophoresis in a 2% agarose gel.
Pyrosequencing
Pyrosequencing was performed using standard procedures
(44). In brief, 160bp of the HHIP promoter region were
ampliﬁed from bisulﬁte-treated DNA using Maxima Hot
start DNA polymerase (Fermentas) and the following pri-
mers: HHIP-Pyro-F, GGGAGGAGAGAGGAGTTT;
HHIP-Pyro-R, Biotin-AACCAACCTCCAAAATACTA
AACC. Sequencing was performed on a PyroMark24
with PyroMark Gold Q24 reagents (Qiagen) and the
sequencing primer HHIP-Pyro-Seq, TTTAGGATTGAG
TTTTTGTTTTAAG.
Additionals
A detailed description of the ChIP procedure as well as the
preparation of nuclear extracts and proteins is given in the
Supplementary Data.
RESULTS
Dnmt1, UHRF1 and USP7 form complexes in solution
and on chromatin
In order to identify Dnmt1 interaction partners, we per-
formed immunoprecipitations with monoclonal antibodies
directed against Dnmt1 using nuclear extracts from HeLa
S3 cells (Figure 1A) and human placenta (data not
shown). Nuclei were isolated and nuclear extracts were
either prepared according to the protocol of Dignam
(45), or by digestion of chromatin with micrococcal
nuclease (MNase) and speciﬁcally associated proteins
were identiﬁed by conventional mass spectrometry of the
excised bands, or determined quantitatively by iTraq
labeling and mass spectrometry (Supplementary
Figure S1). Besides the known interaction partners
UHRF1 (N), only present in the MNase-treated extract,
and PCNA (P) (13,21,46), we observed a strong enrich-
ment of the protein USP7 (U) in both kind of nuclear
extracts (Figure 1A).
To verify the speciﬁc interaction of the endogenous
proteins, immunoprecipitations with antibodies speciﬁc
for Dnmt1, UHRF1 and USP7 were performed, and the
presence of the other proteins was tested by Western Blot
analysis (Figure 1B and Supplementary Figure S2).
Immunoprecipitation of Dnmt1 showed co-precipitation
of UHRF1 and USP7. Vice versa, immunoprecipitation
of UHRF1 and USP7 showed interaction with the other
proteins of interest revealing an interaction of all three
proteins in vivo. Furthermore, digestion of endogenous
DNA by DNaseI followed by immunoprecipitation
demonstrated that these interactions are direct and not
mediated by their independent binding to neighboring
DNA elements (Supplementary Figure S2). However, the
interaction of Dnmt1 with UHRF1 was signiﬁcantly
weaker after DNaseI digestion, suggesting that the com-
plex with UHRF1 is stabilized on chromatin. To further
dissect the interaction of USP7 with Dnmt1 and UHRF1
in vivo, we performed gelﬁltration analysis of the nuclear
extracts (Dignam-extract, ‘MNase’-extract) analyzing
the migration behavior of the three proteins (Figure 1C
and D). The major fractions of Dnmt1 and USP7 signiﬁ-
cantly co-migrated between 440 and 669kDa in the
Dignam-extract, whereas the majority of UHRF1 was
not co-fractionating, but migrating at lower molecular
weight. However, if the MNase-treated extract was used,
we observed co-migration of Dnmt1, UHRF1 and USP7
suggesting the stabilization of the trimeric interaction by
its interaction with chromatin (Figure 1D). Analysis of the
fractions on SDS–PAGE following silver staining of pro-
teins clearly shows the presence of histones in the fractions
of UHRF1 in the ‘MNase’-treated extract but not in the
Dignam-extract (Supplementary Figure S1D and E). As
UHRF1 was shown to be tightly associated with chroma-
tin (13,15,16), our data suggest a ‘soluble’ Dnmt1/USP7
complex to exist when Dnmt1 is detached from chro-
matin and that a trimeric complex with UHRF1 forms
at the chromatin target sites in vivo. The HDAC1
protein was recently shown to form interactions with
USP7, UHRF1 and Dnmt1 (47); however, none of our
gelﬁltration experiments could reveal a major fraction of
HDAC1 co-migrating with the target proteins (Figure 1C
and D).
Dnmt1 and UHRF1 interact with USP7 in vitro
To identify the protein domains mediating the inter-
actions, we puriﬁed the recombinant full-length proteins,
the TS domain (amino acid 316–601) of Dnmt1, the SRA
domain (amino acid 435–586) of UHRF1 and the TRAF
domain (amino acid 1–215; U-1), the proteolytic core do-
main (amino acid 212–561; U-2), the C-terminal domain
(amino acid 561–916; U-3) and the C-terminus (amino
acid 913–1102; U-4) of USP7. The puriﬁed proteins were
used in in vitro pull-down experiments to reveal the
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and S4). Dnmt1 efﬁciently co-precipitated USP7 in vitro and
we were able to map the interaction site of Dnmt1 to the TS
domain (Figure 2B). Vice versa USP7 interacted with
Dnmt1 and the TS domain as expected. The TS domain does
interact at the same time with UHRF1, an interaction that
was also shown previously (21). So far the data suggest two
dimeric complexes, i.e. Dnmt1/USP7 and Dnmt1/UHRF1.
However, we observed as well a direct interaction between
UHRF1 and USP7 indicating the potential existence of
three different dimeric complexes. Immunoprecipitation
experiments using the individual USP7 domains showed
that UHRF1 interacts with the TRAF domain (amino
acid 1–215, U-1), whereas Dnmt1 and the TS domain were
bound by domain 3 of USP7 (amino acid 561–916, U-3)
(Figure 2C). In contrast to Dnmt1, the de novo DNA
methyltransferases, Dnmt3a and Dnmt3b2 preferentially
interacted with the TRAF domain of USP7
(Supplementary Figure S4). Furthermore, the SRA
domain of UHRF1 mediated the interaction with both
Dnmt1 and USP7 (Figure 2C). Taken together, our
in vitro studies allow the discrimination of the following
dimeric complexes (Figure 2D): a Dnmt1/UHRF1 inter-
action between the TS and the SRA domain, an association
of UHRF1 and USP7 mediated between the SRA and the
TRAF domain, and a Dnmt1/USP7 complex between the
U-3 and TS domains, respectively. Moreover, all interactions
also suggest the formation of a trimeric complex of USP7,
Dnmt1 and UHRF1, arguing for a direct interaction on
chromatin in vivo.
USP7 prevents UHRF1 from autoubiquitinylation in vitro
and regulates its stability in vivo
To study the role of the USP7 deubiquitinase activity with
respect to the regulation of Dnmt1 and UHRF1 protein
stability, the expression of USP7 was either down- or
upregulated in doxycycline inducible LS174T cells
(Figure 3A). In agreement with previous studies, knock-
down (LS88 cells) and overexpression (LS89 cells) of
USP7 resulted in stabilization of p53 and thus increase
of p53 levels (25–28). Dnmt1 protein levels decreased
after 3 days of USP7 knockdown, when USP7 levels
were the lowest (Figure 3A), conﬁrming the observation
of Wang and colleagues (47). More signiﬁcant, UHRF1
protein levels decreased or increased after down- or
upregulation of USP7, respectively (Figure 3A). This in-
dicates that USP7 affects the stability of Dnmt1 and
UHRF1 protein in vivo. Due to the strong and reprodu-
cible effects, we further evaluated the stability of the
UHRF1 protein. We used the p53 ( / ) non-small lung
cancer cell line H1299 to avoid p53-dependent side effects.
In order to address whether UHRF1 is turned over in the
ubiquitin dependent proteasomal pathway, cells were
treated with cycloheximide and the proteasome inhibitor
MG132 (48). Incubation of the cells with cycloheximide
resulted in a gradual decrease of UHRF1 protein levels
(Figure 3B). The addition of MG132 clearly stabilized
UHRF1 protein levels in the presence of cycloheximide,
indicating that UHRF1 is degraded via the proteasome-
dependent degradation pathway.
Figure 1. Dnmt1, UHRF1 and USP7 interact with one another in vivo.( A) USP7 is identiﬁed as a new interaction partner of Dnmt1. Dnmt1 was
immunoprecipitated from nuclear extracts (Dignam-extract and MNase-extract) and subjected to SDS–PAGE and Coomassie blue staining. Protein
bands [(U) USP7, (P) PCNA, (N) UHRF1] speciﬁc for the Dnmt1-IP were identiﬁed by MS analysis (ctrl: proteinG sepharose only). Precipitated
Dnmt1 (D) and the molecular weight marker (M) are indicated. (B) Immunoprecipitation of endogenous proteins of the MNase treated extract with
the indicated antibodies. Co-precipitated proteins were detected by Western Blot. 2% of the input (In), 10% of the ﬂowthrough (Ft), 10% of the
control beads (PG: ProteinG Sepharose) and 10% of the antibody coupled beads (B) were loaded. (C and D) HeLa S3 nuclear extracts
[Dignam-extract (C) and MNase-extract (D)] were applied on a supererose6 gelﬁltration column (GE Healthcare). Every second fraction was
analyzed on SDS–PAGE following western blot analysis with the indicated antibodies. Load (L), void and the migration of the molecular weight
reference proteins are indicated.
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E3-ubiquitin ligases ICP0 (49), Chfr (50) and Mdm2 (51)
from autoubiquitinylation, thereby stabilizing their protein
levels. We therefore transfected USP7 into H1299 cells to
monitor the effect of USP7 on the stability of transfected
and endogenous UHRF1 protein (Figure 3C and D). As
seen before, cycloheximide treatment led to gradual
decrease of UHRF1 levels, but also affected the protein
stability of USP7 (timepoints 12–48h). Notably, the tran-
siently increased USP7 levels were sufﬁcient to stabilize
the exogenous and endogenous UHRF1 protein (time-
points: 8–24h) compared to control cells not transfected
with USP7. Transfection of increasing amounts of USP7
following cycloheximide treatment for 24h (Figure 3E)
stabilized UHRF1 protein levels in an USP7-dose-
dependent manner. Taken together, these data indicate
that USP7 stabilizes UHRF1 protein levels in vivo and sug-
gest that USP7 removes ubiquitin adducts from UHRF1
and therefore prevents proteasomal degradation of
UHRF1.
To test whether USP7 directly inﬂuences the auto-
ubiquitinylation activity of the RING-ﬁnger E3-ubiquitin
ligase UHRF1 (15,16,23), we performed in vitro auto-
ubiquitinylation reactions of UHRF1 in the presence of
either USP7 or the catalytically inactive mutant USP7
C223S (49) (Figure 3F and Supplementary Figure S5B).
The activity of the enzymes and the assay conditions
were initially optimized to allow quantiﬁcation of enzym-
atic conversion of the substrates, when required
(Supplementary Figures S5A and S6). UHRF1 exhibits
in vitro autoubiquitinylation activity revealing mono- to
tetra-ubiquitin adducts. However, it has to be mentioned
that the assay cannot discriminate between the addition of
ubiquitin-chains and the addition of multiple mono-
ubiquitin molecules on UHRF1. Interaction of USP7
C223S with UHRF1 reduced the autoubiquitinylation
activity. However, active USP7 completely abolished the
autoubiquitinylation of UHRF1 by removal of ubiquitin
adducts. Accordingly, these data clearly indicate that
USP7 regulates UHRF1 levels in vivo, and counteracts
autoubiquitinylation activity of UHRF1 by removing
ubiquitin adducts.
USP7 stimulates the DNA methylation activity of Dnmt1
in vitro and in vivo
Next, we tested in ChIP assays whether USP7 co-localizes
with Dnmt1 and UHRF1 on selected silenced genes in vivo
(Figure 4A). Genes were selected according to their
reduced expression levels, as determined by quantitative
mRNA analysis compared to the expression levels of the
TBP gene. The selected genes were either completely
silenced SFRP1, IGFBP3, HHIP or active to only 6.6%
(HOXA7). Active genes exhibiting high mRNA levels
and correspondingly high RNA Polymerase II and low
Dnmt1 binding levels were not studied (Supplementary
Figure S7). Besides the HOXA7 locus (52), as a previously
published control, we show that Dnmt1 localizes as well
to the SFRP1, IGFBP3 and HHIP loci together with
UHRF1 and in absence of RNA Polymerase II. In agree-
ment with our biochemical characterization we observed
an enrichment of USP7 at the SFRP1, IGFBP3, HHIP
and HOXA7 loci together with Dnmt1 and UHRF1,
Figure 2. Dnmt1, UHRF1 and USP7 form a trimeric complex. (A) Schematic representation of the domains of Dnmt1, USP7 and UHRF1 (proteins
and domains are not in scale). TS (Targeting domain, amino acid 316–601), cat (C-terminal catalytic domain of Dnmt1). U-1 (TRAF domain, amino
acid 1–215), U-2 (catalytic domain, amino acid 212–561), U-3 (C-terminal domain, amino acid 561–916), U-4 (C-terminus, amino acid 913–1102).
UBQ (ubiquitin-like domain), PHD (plant homeodomain domain), SRA (SET-Ring ﬁnger associated domain, amino acid 435–586), RING (Ring
ﬁnger domain). (B) Co-immunoprecipitation assay to determine the interaction of recombinant proteins with protein-speciﬁc antibodies. Detection of
co-precipitated proteins via western blot. Input (In, 1.0%), protein G sepharose (PG, 20%), ‘speciﬁc beads’ (B, 20%), antibodies used for
immunodetection are indicated. The Dnmt1-speciﬁc antibody DNM-2C1 recognizes the TS-domain and was used for IP and WB. (Asterisks)
Five times shorter exposure of the input signal of UHRF1. (C) GST pull-down assay interaction analysis, using GST, the indicated
USP7-domains and the SRA domain fused to GST with Dnmt1, TS-domain, USP7 and UHRF1. The bound proteins were separated and
plotted with the respective antibodies. Input (In, 20%); GST or GST-fusion domains (25%). (D) Schematic overview of the protein interactions
and protein-domains involved.
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complex on DNA.
To address the effect of the Dnmt1 interacting proteins
UHRF1 and USP7 on the DNA methylation activity of
Dnmt1, we performed a MSP analysis upon knockdown
of UHRF1 and USP7, respectively (Figure 4B).
Downregulation of UHRF1 by siRNA resulted in a
robust demethylation at the SFRP1, IGFBP3, HHIP
and HOXA7 loci. Similarly, knockdown of USP7
resulted in detectable demethylation of all loci analyzed,
albeit to a lower degree as UHRF1 (Figure 4B). The quan-
titative examination of the HHIP promoter region by
pyrosequencing revealed a mean decrease in CpG methy-
lation of 7.6 versus 36.4% upon USP7 and UHRF1
knockdown, respectively (Figure 4C).
USP7 stimulates the DNA methylation activity of Dnmt1
USP7 forms a soluble complex with Dnmt1 in solution
and a trimeric complex with UHRF1 in chromatin. We
addressed the question whether the interaction of USP7,
UHRF1 or USP7/UHRF1 with Dnmt1 would affect its
DNA methylation activity in vitro. The afﬁnities of USP1,
UHRF1 and Dnmt1 toward DNA and the DNA
methyltransferase assays were optimized to allow the
quantitative and qualitative analysis of these reactions
(Figure 5A–C; Supplementary Figures S6, S8 and S9).
Although siRNA mediated knockdown of UHRF1 led
to reduced DNA methylation in vivo (Figure 4B and C),
we did not detect an effect of UHRF1 on the Dnmt1-
dependent DNA methylation activity (Figure 5C). In
agreement with previous data, this suggests that UHRF1
may solely serve as a recruitment platform determining the
location of DNA methylation rather than inﬂuencing the
activity of Dnmt1 (13,14). Accordingly, we observed a
reduction of DNA methylation levels at the SFRP1 and
HHIP genes after USP7 knockdown (Figure 4B and C).
Strikingly, both the in vitro maintenance and de novo
DNA methylation activity of Dnmt1 were stimulated
2-fold in the presence of USP7 (Figure 5D). USP7 and
UHRF1 do inhibit Dnmt1-dependent DNA methylation
Figure 3. USP7 regulates the stability of UHRF1 in vivo and in vitro.( A) LS174T adenocarcinoma cells (LS174TR1, parental) were treated with
doxycycline (dox, 1.0mg/ml) to induce USP7 knockdown (LS88 knockdown) or overexpression of USP7 (LS89 over expr.). Cells were harvested at
the indicated days and a WCE was prepared. Samples were subjected to SDS–PAGE and western blot analysis with the indicated antibodies. (B)
H1299 cells were treated with cycloheximide (CHX, 100mg/ml) and proteasome inhibitor MG132 (20mM) for the indicated time and subsequently
treated as described in (A). (C) H1299 cells were transfected with 700ng Flag-UHRF1 DNA without or with 1.4mg HA-USP7 DNA. Cells were split
36h post-transfection, treated with CHX for the indicated time and analyzed as described in (A). (D) Same as for (C) but only transfection of 2.0mg
HA-USP7 DNA. (E) H1299 cells were transfected with 500ng Flag-UHRF1 DNA and increasing amounts of HA-USP7 DNA (0, 500, 1000, 1500,
2000ng). Forty-eight hours post-transfection cells were treated with CHX for 24h and subsequently analyzed as described in (A). (F) In vitro
autoubiquitinylation of UHRF1 in the absence or presence of either catalytically active USP7 or inactive USP7 C223S and Flag-tagged ubiquitin was
analyzed (substoichiometric USP7 levels were used; 1/5th and 1/50th molar ratio with respect to UHRF1). Proteins were separated on SDS–PAGE
and Flag-tagged ubiquitin adducts were detected by western blot with antibodies against the Flag-tag.
Nucleic Acids Research, 2011,Vol.39, No. 19 8361activity when quantitatively bound to DNA, limiting the
accessible substrate for Dnmt1 (Supplementary Figure S8).
Therefore, the DNA substrate was used in large excess
(3-to 24-fold molar ratio), suggesting that USP7 modu-
lates Dnmt10s enzymatic activity rather than acting as a
recruitment factor. Furthermore, USP7 exerts a stimula-
tory effect on the methylation activity of Dnmt1 even in
the presence of UHRF1, which is in agreement to the
in vivo data (Figures 4 and 5E). Hence, we identiﬁed
USP7 as the ﬁrst factor that has a stimulatory effect on
the enzymatic activity of Dnmt1. Furthermore, we
describe USP7 as a regulator of UHRF1 protein stability,
hence directly affecting Dnmt1-dependent DNA methyla-
tion efﬁciency.
DISCUSSION
Dnmt1 has been extensively described and studied as an
epigenetic factor transiently interacting with many other
chromatin-associating proteins (10,11). In fact, so far only
Figure 4. USP7 associates with Dnmt1 and UHRF1 on silenced genes in vivo.( A) Chromatin immunoprecipitation (ChIP) was performed with
formaldehyde cross-linked HCT-116 cells and the indicated antibodies. The average of three independent ChIP experiments for Dnmt1, UHRF1,
USP7 and RNAPII are shown. Standard deviations, target genes of interest and antibodies used for ChIP are indicated. The enrichment of speciﬁc
IP versus IgG background is plotted. The relative expression levels of these genes compared to the TBP gene are given. (B) Promoter regions of the
SFRP1, IGFBP3, HHIP and HOXA7 genes were analyzed for methylated (M) and unmethylated (U) CpG sites by MSP in the presence or absence
of USP7 and UHRF1. Proteins were depleted by RNAi-mediated knockdown and the MSP analysis was performed with bisulﬁte-treated genomic
DNA from HCT-116 cells. Representative images of MSP experiments are given. (C) Quantitative analysis of DNA methylation levels after UHRF1
and USP7 knockdown. Pyrogram trace obtained after pyrosequencing analysis of part of the HHIP promoter region containing 13 CpG sites (with
potentially methylated cytosines shaded in gray). The y-axis represents the signal intensity in arbitrary units, while the x-axis shows the dispensation
order. The percentage of DNA methylation at individual CpG positions of the HHIP promoter of cells transfected with non-targeting control, USP7
and UHRF1 siRNAs are shown below the pyrogram.
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been biochemically puriﬁed (12).
In this study, we identiﬁed two novel Dnmt1-containing
complexes by means of immunoprecipitation and SEC
analysis. First, we observed a strong interaction of
Dnmt1 and USP7, forming a soluble dimer complex
in vivo. Second, Dnmt1/USP7 could further interact with
UHRF1 and strongly associated as a trimeric complex on
chromatin (Figures 1, 2 and 4A).
UHRF1 was shown to be tightly associated with chro-
matin and to bind to hemi-methylated DNA (hmDNA),
acting as a recruitment factor for Dnmt1 (13–15). We
conﬁrmed the preferential binding of UHRF1 to
hmDNA (Supplementary Figure S8A) and demonstrated
co-binding of Dnmt1 and UHRF1 to silenced genes
in addition to the subunit USP7 (Figure 4A). Upon
UHRF1 knockdown, we observed a reduction of the
methylation status of the studied genes (Figure 4B and
C). As UHRF1 did not stimulate the DNA methylation
activity of Dnmt1 in vitro, this clearly indicates that
UHRF10s major function is to ensure Dnmt1 guidance
to hmDNA, as previously shown (13,14). USP7 had
been described to protect RING-ﬁnger E3-ubiquitin
ligases from autoubiquitinylation, thereby stabilizing
their protein levels (49–51). We were able to show that
USP7 levels did directly inﬂuence the stability of
UHRF1 and was capable to de-ubiquitinylate UHRF1
in vitro (Figure 3F). Transfection of USP7 into H1299
cells stabilized exogenous and endogenous UHRF1
protein upon cycloheximide treatment (Figure 3).
Altogether, our data indicate that USP7 removes
ubiquitin moieties from UHRF1 and thereby inhibits its
proteasomal degradation in the cell. The knockdown of
USP7 affected the DNA methylation status of the studied
target gene loci, suggesting that it serves as an amplifying
module within the trimeric methylating complex, ensuring
maintenance of DNA methylation. An effect that appar-
ently resides from UHRF1 stabilization and the
upregulation of the Dnmt1 DNA methylation activity,
as discussed below. Consistent with the assumption of a
close collaboration of those proteins, USP7 knockout
mice showed lethal defects in early embryonic develop-
ment (33), reminiscent of Dnmt1 knockout mice (7).
As the expression of UHRF1 peaks during G1/S-phase
transition and is downregulated during G0 and G1 (40,53),
USP7 could stabilize UHRF1 during S-phase by con-
stantly removing ubiquitin moieties. After replication,
USP70s activity could be modulated by post-translational
modiﬁcation (54), eventually leading to degradation of
UHRF1. Subsequently, the Dnmt1/USP7 complex would
dissociate from chromatin consistent with the observation
of a diffuse localization of Dnmt1 in the nucleoplasm
during G1 and G0 (20).
It was recently suggested that Dnmt1 is stabilized by
HDAC1 and USP7 in a cell cycle-dependent manner
(47). The authors suggested a stable complex of Dnmt1
with HDAC1 that we did not observe in our immunopre-
cipitation and gelﬁltration assays (Figure 1C and D;
Supplementary Figure S2B). This could be related to the
fact that we used non-synchronous cells for our puriﬁca-
tions and minor amounts of Dnmt1–HDAC1 complexes
could have been overlooked, as the published effect is cell
Figure 5. USP7 activates the DNA methylation activity of Dnmt1 in vitro.( A) Recombinant Dnmt1, USP7 and UHRF1 proteins, puriﬁed from
baculovirus-infected Sf21 insect cells and E. coli cells via the His-tag. Proteins were separated on a SDS–PAGE and stained with Coomassie blue. (B)
Dnmt1 dependent in vitro DNA methylation on non-methylated (nm DNA) and hemi-methylated DNA (hm DNA) was performed with increasing
amounts of Dnmt1 and an excess of DNA (4.0mM) for 15min. The transfer of the 3H-methyl group onto the DNA was measured and plotted. (C)
Dnmt1-dependent DNA methylation reactions in the presence of increasing amounts of UHRF1 were performed in excess of hmDNA for two
different time points (5 and 15min). The relative activity was plotted and UHRF1 ratios to DNA or Dnmt1 are given. (D) Same as for (C) but using
USP7 on non-methylated (nm) and hemi-methylated DNA (hm). (E) Same as for (C) but ﬁxed amounts of Dnmt1 and USP7 were incubated with
increasing levels of UHRF1 as indicated. The relative methylation activity is plotted and molar ratios of UHRF1:Dnmt1, USP7:Dnmt1,
UHRF1:DNA and USP7:DNA are given.
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we see a comparable destabilization of Dnmt1 after 3 days
of USP7 knockdown. The mild destabilization of Dnmt1
would be further potentiated by the HDAC1 activity, as
described (47).
Besides controlling the ubiquitination status of
UHRF1, USP7 plays an additional role in this complex
and stimulates both the maintenance and the de novo DNA
methylation activity of Dnmt1 in vitro (Figure 5). So far
USP7 is the ﬁrst factor to be shown to exhibit such an
activity. Immunoprecipitation and gelﬁltration experi-
ments suggest that the majority of Dnmt1 may be
associated with USP7 and as shown by Wang and col-
leagues USP7 does also regulate the stability of Dnmt1
(47). Accordingly, USP7 acts in two ways to stimulate
the Dnmt1-dependent DNA methylation activity, i.e. via
stimulating its activity and protecting the protein from
degradation. The 2-fold activation of the Dnmt1 activity
in the Dnmt1/USP7 complex could not be further
activated by the addition of UHRF1 conﬁrming the
notion that UHRF1 is mainly required to target the
complex to hemi-methylated DNA.
From these data, we propose a new role for USP7 as the
epigenetic regulator of Dnmt1-dependent DNA methyla-
tion activity. First, the enzymatic activity of Dnmt1 in
complex with USP7 is directly stimulated by USP7 by
factor of two. Second, the Dnmt1-USP7 dimeric
complex is recruited to the sites of methylation by
UHRF1, forming a trimeric complex on chromatin. As
the protein stability of UHRF1 is regulated by USP7,
the Dnmt1-USP7 association on chromatin and hence
the DNA methylation efﬁciency is controlled by USP7.
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